The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YES

Assessing tissue damage in multiple sclerosis: a biomarker approach

(2014) J. Burman et al.   ACTA NEUROLOGICA SCANDINAVICA

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal

EFNS guidelines on disease-specific CSF investigations

(2009) F. Deisenhammer et al.   EUROPEAN JOURNAL OF NEUROLOGY